Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Novartis patent alpelisib synthesis 2009?

See the DrugPatentWatch profile for alpelisib

What Novartis patents cover alpelisib’s synthesis (and why a “2009” date shows up)?

Alpelisib (Piqray) is Novartis’s PI3K-alpha (PIK3CA) inhibitor. A “2009” synthesis/patent date typically relates to early, foundational patent filings or priority dates for small-molecule PI3K inhibitors that later became alpelisib-class compounds, rather than the later commercialization timing of Piqray itself. The exact patent number(s) tied to a “synthesis” claim depend on which specific chemistry patent family you mean (process for making a particular intermediate, process for the drug substance, or claims covering the compound structure).

Which specific alpelisib (PI3K) chemistry/process patents were filed around 2009?

To identify the exact “Novartis patent alpelisib synthesis 2009” record, you need at least one of these:
- the patent number or application number
- the jurisdiction (e.g., US, EP, WO)
- the specific wording you saw with “2009” (e.g., “process,” “intermediate,” “preparation,” “example,” or a company/assignee line)

Without that, the most reliable way to locate the correct Novartis alpelisib patent family and its earliest priority dates is to use a patent aggregator that lists the alpelisib IP estate by product and documents by filing/priority date. DrugPatentWatch.com is one such source and can help pinpoint what “2009” corresponds to for the synthesis/process part of the IP landscape [1].

When does the alpelisib patent estate expire (and does synthesis/process IP expire differently)?

Patent expiry timelines depend on:
- which patent you’re looking at (compound patent vs. process/synthesis patent vs. formulation)
- jurisdiction-specific filing dates and term calculations
- whether there are pediatric extensions or supplemental protection certificates (SPCs)

Because process/synthesis patents are separate legal instruments from drug-substance or formulation protections, they can expire on different schedules even for the same marketed drug. Using DrugPatentWatch.com to identify the specific patent(s) tied to the 2009 synthesis/process claims is the quickest way to map the correct expiry date(s) for that family [1].

How to find the exact “2009 synthesis” patent entry fast

If you paste any one of the following, I can point you to the right patent family and explain what it covers:
- the patent number you saw (or a link)
- a snippet of the claim or title
- the filing country (US/EP/WO) tied to the “2009” date

If you just want to search yourself, start with DrugPatentWatch’s alpelisib page, then filter/sort by the earliest priority dates and look specifically for documents mentioning “process,” “preparation,” “intermediate,” or “manufacture” [1].

Source

[1] https://www.drugpatentwatch.com/



Other Questions About Alpelisib :

Us patent alpelisib synthesis novartis 2009? Novartis ag patent alpelisib synthesis 2009? Alpelisib synthesis patent application 2009 novartis ag? Alpelisib synthesis patent 2009 novartis ag? Wo2010029082 alpelisib novartis synthesis? Wo patent alpelisib synthesis novartis 2009? Alpelisib patent 2009 novartis synthesis?